Fangzhou and Youcare Partner to Scale AI-Driven Chronic Care Across China
Fangzhou Inc. (HKEX: 06086) and Youcare Pharmaceutical Group (SH: 688658) have signed a strategic collaboration to digitize chronic disease services with AI. The focus: build full-lifecycle, patient-centered care that's more accessible, efficient, and precise.
This move meets China's push to upgrade chronic disease management and shift from treatment-centered to patient-centered models. For operators and executives, the signal is clear-care pathways are moving closer to home with AI stitched through every step.
What the partnership covers
- Co-develop digital systems: Combine Youcare's medicines and clinical expertise with Fangzhou's AI stack (consultation, medication management, post-visit follow-up) to support full-cycle chronic care.
- Expand health management services: Scale programs in cardiovascular, infectious disease, and endocrine care, improving access to quality therapies and professional support.
Fangzhou's "AI + H2H (Hospital-to-Home)" model already includes an AI physician assistant, AI medication assistant, AI health manager, and an AI content engine. In 2026, the company plans to extend AI across every stage of the chronic care value chain.
Why it matters for management
- Model shift: Patient-centered, data-informed care can raise adherence, reduce avoidable visits, and lower cost-to-serve.
- Ecosystem play: Platform + pharma integration improves reach, real-world data capture, and therapy support at scale.
- Policy fit: The roadmap supports national targets under Healthy China 2030.
Signals to watch
- Patient enrollment growth in chronic programs and retention over 6-12 months
- Medication adherence and refill cadence by therapy area
- Physician activation and repeat usage across Fangzhou's 229,000-doctor network
- Time-to-intervention and average cost-to-serve per patient
- Regulatory milestones and hospital integration depth in target specialties
Execution risks to manage
- Data governance: Privacy, consent, and cross-institution data-sharing
- Clinical validation: Ongoing model performance and safety monitoring
- Workflow fit: Integration with hospital systems and clinician trust
- Supply chain and access: Therapy availability, affordability, and reimbursement
Action steps for healthcare leaders
- Map your chronic pathways and flag high-friction steps suited to AI assistance (screening, titration, follow-up, adherence)
- Stand up a cross-functional squad (clinical, product, data, compliance) with clear decision rights
- Define 3-5 outcome metrics per program (e.g., adherence, readmissions, PROMs) and build feedback loops
- Secure data-sharing agreements and informed consent workflows early
- Upskill managers on AI governance and vendor evaluation: AI for Executives & Strategy
Leaders' perspective
Zhou Feng, Chief Strategy Officer of Fangzhou, called the collaboration a practical path to a new healthcare ecosystem-combining AI, operations, and patient services to advance intelligent chronic care.
Yu Pengfei, Director and Deputy General Manager of Youcare, said the move extends the company's focus from pharmaceutical supply to broader health services and could increase the real-world reach of its therapies.
Company snapshots
Fangzhou Inc. is China's leading online chronic disease management platform with 52.8 million registered users and 229,000 physicians (as of June 30, 2025). More at investors.jianke.com.
Youcare Pharmaceutical Group (founded 2001; listed 2020) is a top-100 Chinese pharmaceutical enterprise spanning new drug R&D, manufacturing, distribution, and international business.
Note: The companies included forward-looking statements; actual results may differ due to multiple factors.
Your membership also unlocks:
